尿激酶型纤溶酶原激活剂及其受体在胰腺癌中表达的意义  

Clinical study on the expression of urokinase plasminogen activator and urokinase plasminogen activator receptor in pancreatic cancer

作　　者：贾彬[1] 韩曙光[1] 闫慧明[1] 

机构地区：[1]山西医科大学第二医院普外科,030001

出　　处：《中国药物与临床》2005年第3期186-189,i002,共5页Chinese Remedies & Clinics

基　　金：山西省自然科学基金资助项(20041119)

摘　　要：目的探讨尿激酶型纤溶酶原激活剂(urokinaseplasminogenactivator,uPA)、尿激酶型纤溶酶原激活剂受体(urokinaseplasminogenactivatorreceptor,uPAR)在胰腺癌中表达的意义。方法用反转录聚合酶链反应(RT鄄PCR)和免疫组织化学方法分别检测uPA、uPAR在85例胰腺癌和10例胰腺炎组织中mRNA和蛋白抗原的表达。HPIAS图像分析各组标本相对密度,t检验各组相对密度差异,字2检验uPA、uPAR与胰腺癌肿瘤临床病理之间的相关性。结果uPA、uPARmRNA和蛋白抗原在胰腺炎组织中低表达,胰腺癌组织中uPA、uPARmRNA和蛋白抗原的高表达,胰腺癌中伴有转移者uPA、uPAR的mRNA和蛋白抗原的表达明显高于无转移者。uPA、uPAR的表达与胰腺癌的转移程度高度相关。结论uPA、uPAR是反映胰腺肿瘤进展和生物学特性的指标。Objective Study the significance of the expression of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) in pancreatic cancer. Methods The expression of uPA,uPAR mRNA and protein antigen was detected by reverst transcriptase polymerase chain reaction (RT-PCR) and immunohistochemi-stry in 85 cases of pancreatic cancer and 10 cases of pancreatitis tissue.Expression density of uPA,uPAR in each group was analyzed with HPIAS image analyzer compared with t test,the correlation between the expression level of uPA,uPAR and malignancy was tested with Chi-square. Results The expression of uPA,uPAR mRNA and antigen in pancreatitis tissue was very low.Expression of uPA,uPAR mRNA and antigen was greatly increased in pancreatic cancer.The level of the uPA,uPAR expression was increased markedly in the group with metastasis compared with non-metastasis.Expression of uPA,uPAR was highly related to the degree of metastasis of pancreatic cancer. Conclusion The study suggests that uPA,uPAR play a role in the process of metastasis,being a good index for estimating prognosis in clinics.

关 键 词：PLASMINOGEN 尿激酶型纤溶酶原激活剂受体 activator 反转录聚合酶链反应 receptor 免疫组织化学方法 UPAR 蛋白抗原 mRNA 相对密度 X^2检验 胰腺癌组织 生物学特性 图像分析 临床病理 肿瘤进展 判断预后 胰腺炎 t检验 

分 类 号：R735.9[医药卫生—肿瘤]